At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 34 enrolled
Drug / intervention
mometasone furoate nasal spraydrug
Likely dose
mometasone furoate nasal spray 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Pilot Trial, Evaluating the Role of Nasonex in the Management of Nasal Obstruction Secondary to Adenoids Hypertrophy in Children
In Brief
A Phase 4 clinical trial evaluating mometasone furoate nasal spray for Adenoids. Completed, enrolled 34 participants.
Detailed Summary
To document the short term \& long term effect of treatment with Nasonex (mometasone furoate nasal spray) in moderate to severe adenoids hypertrophy (which cause \> 50% obstruction of the posterior choanae).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenoids
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
Primary CompletionSep 2009
First PostedApr 2010
TodayJul 2026
First PostedApr 2, 2010
Enrollment StartAug 1, 2008
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.3 years ago
Interventions
mometasone furoate nasal spraydrug
One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months